ERVIN EPSTEIN, MD

CO-FOUNDER, PRESIDENT, DIRECTOR, CMO

Senior Scientist, Children’s Hospital of Oakland Research Institute

  • Practicing dermatologist; Co-discovered aberrant hedgehog signaling in basal cell carcinoma

  • Investigator-initiated clinical trials of vismodegib, celecoxib, tazarotene in Gorlin syndrome

Mark de Souza, PhD

EXECUTIVE CHAIRMAN

Biotechnology entrepreneur in the rare disease and dermatology space

  • President & CEO, Chromaderm, Inc., FIBRX Tissue Repair, Inc., SCIDEC Therapeutics, Inc.

  • Former Founding President & CEO, Lotus Tissue Repair, Inc. (acquired by Shire)
 

GERD KOCHENDOERFER, PHD

VP OF TECHNICAL OPERATIONS & PROGRAM MANAGEMENT

20 + years experience at all phases of drug development through commercialization.

  • Formeryly Head of Technical Operations and member of Executive Team, Depomed

  • Senior management positions at Depomed and Fibrogen

Curtis Scribner, MD

REGULATORY ADVISOR

 

Regulatory consultant with >30 years experience, including 10 years at FDA

  • Former SVP Medical and Regulatory Affairs, RRD International, LLC and lead Regulatory positions at Quintiles and Intarcia
 

JEAN TANG, MD, PHD

CO-FOUNDER, DIRECTOR

Associate Professor of Dermatology, Stanford University

  • Practicing dermatologist

  • Investigator-initiated trials of vismodegib in Gorlin syndrome, vismodegib as an adjuvant to surgery in high-risk basal cell carcinoma, and oral and topical itraconazole in basal cell carcinoma

Philip Beachy, PhD

CO-FOUNDER

Professor of Biochemistry and Developmental Biology, Stanford University, HHMI Investigator

  • National Academy of Sciences, American Academy of Arts and Sciences

  • Co-founder, Fate Therapeutics Inc.
 

Neil Kumar, PhD

DIRECTOR

CEO and Co-Founder, BridgeBio

  • Former Principal, Third Rock Ventures

  • Former Interim Vice President, Business Development, MyoKardia, Inc.

FRANK MCCORMICK, PHD

DIRECTOR

Director of UCSF Helen Diller Family Comprehensive Cancer Center. Co-Founder, BridgeBio

  • Fellow of the Royal Society

  • Co-Founder and former CSO, Onyx Pharmaceuticals (acquired by Amgen)